

# CITATION REPORT

List of articles citing

Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia

DOI: 10.1212/01.wnl.0000183055.81056.5c  
Neurology, 2005, 65, 1423-9.

**Source:** <https://exaly.com/paper-pdf/38750132/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
221	Dystonia. <b>2006</b> , 355, 818-29		205
220	Treatment of dystonia. <b>2006</b> , 6, 863-86		25
219	Botulinum toxin: clinical use. <b>2006</b> , 12, 331-55		86
218	Bibliography. Current world literature. Neuromuscular diseases: nerve. <b>2006</b> , 19, 487-512		
217	Clinical use of non-A botulinum toxins: botulinum toxin type B. <b>2006</b> , 9, 121-5		60
216	Botulinum toxin therapy for cervical dystonia. <b>2006</b> , 9, 145-8		76
215	Treatment of dystonia. <b>2006</b> , 5, 864-72		245
214	Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. <i>Neurology</i> , <b>2006</b> , 67, 2233-5	6.5	86
213	Treatment of headaches with botulinum toxin. <b>2006</b> , 6, 313-22		9
212	Clinical Diagnosis and Management of Dystonia. <b>2007</b> ,		4
211	Cervical Dystonia. <b>2007</b> , 20, 449-457		1
210	Botulinum toxin in movement disorders. <b>2007</b> , 27, 183-94		13
209	Botulinum toxin type B improves the speed of reaching in children with cerebral palsy and arm dystonia: an open-label, dose-escalation pilot study. <b>2007</b> , 22, 116-22		39
208	Iatrogenic botulism in a child with spastic quadriplegia. <b>2007</b> , 22, 1235-7		17
207	TREATMENT OF DYSTONIA. <b>2007</b> , 13, 94-121		3
206	An in vitro assay for detection of tetanus neurotoxin activity: using antibodies for recognizing the proteolytically generated cleavage product. <b>2007</b> , 21, 1641-9		16
205	Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. <b>2007</b> , 29, 1325-37		64

204	Treatment of dystonia. <b>2007</b> , 13 Suppl 3, S362-8		25
203	Therapeutic Uses of Botulinum Toxin. <b>2007</b> ,		2
202	Botulinum toxin in poststroke spasticity. <b>2007</b> , 5, 132-8		58
201	The management of cervical dystonia. <b>2007</b> , 8, 129-40		14
200	Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. <i>Drugs</i> , <b>2007</b> , 67, 669-83	12.1	98
199	Sialorrhea in Parkinson's disease: a review. <b>2007</b> , 22, 2306-13		94
198	Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. <b>2008</b> , 117, 73-84		44
197	Botulinum toxin in the management of dystonia. <b>2007</b> , 9, 224-33		2
196	Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea. <b>2007</b> , 12, 275-90		24
195	Future aspects of botulinum neurotoxins. <b>2008</b> , 115, 567-73		16
194	The treatment of cervical dystonia with botulinum toxins. <b>2008</b> , 115, 579-83		23
193	Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. <b>2008</b> , 255, 545-50		40
192	Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. <b>2008</b> , 23, 510-7		101
191	Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. <b>2008</b> , 23, 1353-60		158
190	Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors. <b>2008</b> , 59, 71-5		18
189	Movement disorder-childhood rating scale: reliability and validity. <b>2008</b> , 39, 259-65		33
188	Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. <b>2008</b> , 26 Suppl 1, 54-65		27
187	Role of botulinum toxin in the treatment of cervical dystonia. <b>2008</b> , 26 Suppl 1, 43-53		8

186	Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i> , <b>2008</b> , 70, 1691-8	6.5	286
185	Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. <b>2008</b> , 26, 126-35		113
184	Botulinum neurotoxins in the treatment of refractory pain. <b>2008</b> , 4, 676-85		58
183	Selective denervation of the levator scapulae muscle: an amendment to the Bertrand procedure for the treatment of spasmodic torticollis. <b>2008</b> , 108, 757-63		13
182	Botulinum toxin type A improves blood flow in vascular thoracic outlet syndrome. <b>2008</b> , 87, 956-9		19
181	Clinical comparisons of botulinum neurotoxin formulations. <b>2008</b> , 14, 289-98		21
180	Botulinum toxin type A in the treatment of patients with cervical dystonia. <i>Biologics: Targets and Therapy</i> , <b>2008</b> , 1	4.4	
179	Comparative Clinical Trials of Botulinum Toxins. <b>2009</b> , 398-405		
178	Unmet Needs and Challenges in the Therapeutic Use of Botulinum Neurotoxins. <b>2009</b> , 360-366		
177	Current clinical applications of botulinum toxin. <b>2009</b> , 15, 3671-80		36
176	Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. <b>2009</b> , 24, 1375-9		85
175	Evolution of stereotypies in adolescents and women with Rett syndrome. <b>2009</b> , 24, 1379-83		13
174	Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore pre-morbid employment status. <b>2009</b> , 24, 1384-7		32
173	Progression of ataxia in patients with Machado-Joseph disease. <b>2009</b> , 24, 1387-90		28
172	Screening for dystonia genes DYT1, 11 and 16 in patients with writer's cramp. <b>2009</b> , 24, 1390-2		11
171	Spasticity. <b>2009</b> , 11, 153-61		16
170	Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. <b>2009</b> , 16 Suppl 2, 14-8		23
169	Treatment of focal dystonias with botulinum neurotoxin. <b>2009</b> , 54, 628-33		55

168	Chemodenervation and nerve blocks in the diagnosis and management of spasticity and muscle overactivity. <b>2009</b> , 1, 842-51	42
167	Cervical dystonia. <b>2009</b> , 4, 639-647	
166	[Different botulinum toxins and their specifications]. <b>2009</b> , 136 Suppl 4, S77-85	5
165	Neurotoxin injection for movement disorders. <b>2010</b> , 16, 131-57	4
164	Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. <b>2010</b> , 33, 243-7	64
163	A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigine in the treatment of cervical dystonia. <b>2010</b> , 33, 22-6	31
162	Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. <b>2010</b> , 17 Suppl 2, 94-108	43
161	Endopeptidase activities of botulinum neurotoxin type B complex, holotoxin, and light chain. <b>2010</b> , 76, 6658-63	8
160	Diston� cervical. <b>2010</b> , 107-125	
159	Temporal characteristics of botulinum neurotoxin therapy. <b>2010</b> , 10, 93-103	16
158	An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia. <b>2010</b> , 120, 703-10	13
157	Hypersialorrh� chez le patient parkinsonien. <b>2010</b> , 1, 7-14	
156	Clinical use of botulinum toxins in oral and maxillofacial surgery. <b>2010</b> , 39, 197-207	36
155	Evaluaci� de calidad asistencial en la utilizaci� de toxina botul�ica para el tratamiento de la espasticidad postictus en adultos. <b>2010</b> , 44, 317-325	
154	Therapeutic challenges in dystonia. <b>2010</b> , 28, 927-40	7
153	Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN� , botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. <b>2011</b> , 308, 103-9	105
152	Adult-onset dystonia. <b>2011</b> , 100, 481-511	26
151	Obturator nerve block with botulinum toxin type B for patient with adductor thigh muscle spasm -a case report-. <b>2011</b> , 24, 164-8	5

150	A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins. <b>2012</b> , 8, 13-25	8
149	Application of botulinum toxin in pain management. <b>2011</b> , 24, 1-6	42
148	Botulinum toxin therapy for cervical dystonia: review of the clinical evidence and ongoing studies. <b>2011</b> , 1, 891-900	4
147	EFNS guidelines on diagnosis and treatment of primary dystonias. <b>2011</b> , 18, 5-18	277
146	Response to EFNS guidelines on treatment of Dystonia article. <b>2011</b> , 18, e60-1; author reply e62	1
145	Response to letter by Dr Neil Murray. <b>2011</b> , 18, e62-e62	
144	Treatment of refractory pain with botulinum toxins--an evidence-based review. <b>2011</b> , 12, 1594-606	71
143	Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. <b>2011</b> , 240-241, 121-8	9
142	Other Non-Motor Symptoms of Parkinson's Disease. <b>2011</b> , 387-393	
141	Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). <b>2011</b> , 11, 140	19
140	Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. <b>2011</b> , 26, 313-9	81
139	Pre-operative evaluations for DBS in dystonia. <b>2011</b> , 26 Suppl 1, S17-22	14
138	Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates. <b>2011</b> , 137, 46-52	7
137	Neues zu neurologischen Bewegungsstörungen 2011. <b>2011</b> , 38, 222-233	
136	Treatment of dystonia. <b>2011</b> , 293-310	
135	Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia. <b>2012</b> , 35, 208-14	54
134	Botulinum toxin type A in cervical dystonia. <b>2012</b> , 25, 23S-28S	5
133	Dystonia. <b>2012</b> , 55-83	1

132	Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains. <b>2012</b> , 217, 1-7	6
131	Botulinum toxins in the treatment of primary focal dystonias. <b>2012</b> , 316, 9-14	19
130	Clinical applications of botulinum toxin. <b>2012</b> , 15, 325-36	120
129	Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. <b>2012</b> , 4, 913-39	93
128	Therapeutic use of botulinum toxin in neurorehabilitation. <b>2012</b> , 2012, 802893	22
127	Treatment of focal dystonia. <b>2012</b> , 14, 213-29	22
126	Botulinum toxin for the treatment of movement disorders. <b>2012</b> , 12, 399-409	31
125	Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. <b>2012</b> , 586, 310-3	64
124	Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. <b>2012</b> , 27, 219-26	57
123	Dystonia rating scales: critique and recommendations. <b>2013</b> , 28, 874-83	103
122	Medical treatment of dystonia. <b>2013</b> , 28, 1001-12	104
121	A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia. <b>2013</b> , 120, 1699-707	39
120	Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. <b>2013</b> , 67, 94-114	171
119	Superficial siderosis of the central nervous system due to chronic hemorrhage from a giant invasive prolactinoma. <b>2013</b> , 20, 1032-4	7
118	Sustained benefit of painful legs moving toes syndrome with botulinum toxin type A. <b>2013</b> , 20, 1031-2	14
117	Botulinum toxin for painful spasms from focal seizures: theoretical considerations and case report. <b>2013</b> , 19, 15-6	3
116	Cervical Dystonia: From Pathophysiology to Pharmacotherapy. <b>2013</b> , 26, 275-282	21
115	Therapeutic Uses of Botulinum Toxin. <b>2014</b> , 05,	3

114	Differential Diagnosis of Movement Disorders in Clinical Practice. <b>2014,</b>	1
113	Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. <b>2014, 13, 875-84</b>	210
112	Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. <b>2014, 14, 91</b>	25
111	Aesthetic uses of the botulinum toxin. <b>2014, 32, 23-36</b>	24
110	Neurosurgery for Spasticity. <b>2014,</b>	9
109	Botulinum Toxin in Pediatric Neurology: Switching Lanes From Death to Life. <b>2015, 2, 2333794X15590149</b>	0
108	Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment. <b>2015, 7, 2321-35</b>	35
107	Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A. <b>2015, 9, 725-31</b>	4
106	Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. <b>2015, 30, 206-13</b>	35
105	Clinical comparison of botulinum toxin in motor and autonomic disorders: Similarities and differences. <b>2015, 107, 68-71</b>	3
104	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. <b>2015, 262, 2201-13</b>	42
103	Botulinum Toxin Treatment of Pain Disorders. <b>2015,</b>	6
102	Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology. <b>2015, 2, 135-141</b>	33
101	Clinical differences between botulinum neurotoxin type A and B. <b>2015, 107, 77-84</b>	49
100	Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials. <b>2015, 107, 89-97</b>	9
99	Economic and Employment Issues in Patients with Dystonia: A Self-report Questionnaire Survey. <b>2016, 7,</b>	1
98	Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?. <b>2016, 12, 147-54</b>	7
97	Botulinum Toxin Injections in Musculoskeletal Disorders. <b>2016, 20, 441-452</b>	11



96	Effectiveness of Botulinum Toxin for Lower Limbs Spasticity after Stroke: A Systematic Review and Meta-Analysis. <b>2016</b> , 23, 217-23	21
95	Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i> , <b>2016</b> , 86, 1818-26	6.5 291
94	Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. <b>2016</b> , 31, 1649-1657	31
93	Neck Pain and Cervical Dystonia: Treatment Outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). <b>2016</b> , 16, 1073-1082	13
92	Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. <b>2016</b> , 10, CD004314	19
91	Disorders of Movement. <b>2016</b> ,	8
90	Botulinum Toxin Treatment of Cervical Dystonia. <b>2016</b> , 36, 47-53	10
89	A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. <b>2016</b> , 263, 772-80	13
88	Botulinum Toxin Therapy for Parkinson's Disease. <b>2017</b> , 37, 193-204	6
87	Botulinum Toxin: From Molecule to Medicine. <b>2017</b> , 37-51	0
86	Botulinum Toxin for Asians. <b>2017</b> ,	7
85	Hyperhidrosis Treatment with Botulinum Toxin. <b>2017</b> , 159-182	
84	BoNT/AB hybrid maintains similar duration of paresis as BoNT/A wild-type in murine running wheel assay. <b>2017</b> , 59, 1-8	9
83	Available treatment options for dystonia. <b>2017</b> , 5, 707-716	6
82	When movement disorders hurt: Addressing pain in hyperkinetic disorders. <b>2017</b> , 44, 110-113	8
81	Botulinum toxin: State of the art. <b>2017</b> , 32, 1131-1138	118
80	Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. <b>2017</b> , 8, 53	39
79	RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. <b>2017</b> , 4, 9	12

78	Immunological aspects of botulinum toxin therapy. <b>2017</b> , 17, 487-494		25
77	Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 35	4-1	43
76	Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. <b>2017</b> , 9, 211-229		1
75	Botulinum Toxin Treatment of Movement Disorders. <b>2018</b> , 20, 4		23
74	Evidence on botulinum toxin in selected disorders. <b>2018</b> , 147, 134-140		8
73	Pain in focal dystonias - A focused review to address an important component of the disease. <b>2018</b> , 54, 17-24		19
72	Treatment of oromandibular dystonia using botulinum toxin injections [Case series and illustrative muscle targeting. <b>2018</b> , 13, 7-16		1
71	Lumbar Sympathetic Block with Botulinum Toxin Type A and Type B for the Complex Regional Pain Syndrome. <b>2018</b> , 10,		12
70	Dystonia. <b>2018</b> , 183-211		
69	Botulinum Toxin Therapy for Cervical Dystonia. 160-166		
68	Meaningful Assessment in Patients with Acquired Brain Injuries. <b>2018</b> , 29, 437-444		
67	Immunogenicity Associated with Botulinum Toxin Treatment. <b>2019</b> , 11,		49
66	Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. <b>2019</b> , 405, 116413		7
65	Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models. <b>2019</b> , 5, eaau7196		18
64	Cervical dystonia: an update on therapeutics. <b>2019</b> , 7, 199-209		
63	Pain in cervical dystonia and the antinociceptive effects of botulinum toxin: what is currently known?. <b>2019</b> , 30, 771-779		7
62	Pallidal neurostimulation versus botulinum toxin injections in the treatment of cervical dystonia: protocol of a randomized, sham-controlled trial (StimTox-CD). <b>2019</b> , 1, 2		
61	Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients. <b>2019</b> , 130, 1066-1073		8

60	The Use of Botulinum Toxin for Treatment of the Dystonias. <b>2021</b> , 263, 107-126	5
59	Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA. <b>2020</b> , 12,	3
58	Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy. <b>2020</b> , 18, e3000618	7
57	Clinical duration of action of different botulinum toxin types in humans. <b>2020</b> , 179, 84-91	11
56	Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial. <b>2020</b> , 77, 461-469	21
55	Novel Native and Engineered Botulinum Neurotoxins. <b>2021</b> , 263, 63-89	5
54	Botulinum Neurotoxins as a Therapeutic. <b>2021</b> , 1-48	
53	A consensus statement on the use of botulinum toxin in pediatric patients. <b>2021</b> ,	1
52	Botulinum Toxin in Movement Disorders: An Update. <b>2021</b> , 13,	27
51	Treatment of dystonia. <b>2021</b> , 353-370.e10	
50	Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders. <b>2014</b> , 51-93	1
49	Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. <i>Neurology</i> , <b>2020</b> , 94, e2109-e2120	6.5 12
48	Pharmacology, immunology, and current developments. <b>2011</b> , 1-14	1
47	Cervical dystonia. <b>2012</b> , 144-158	3
46	Botulinum toxin injections for neurological disorders: Experience between 1994 and 2019. <b>2020</b> , 37, 197	0
45	Sore throat as a side effect of abobotulinum toxin A injection for upper limb spasticity after stroke: A case report. <b>2020</b> , 66, 88-91	1
44	Diffusion of botulinum toxins. <b>2012</b> , 2,	19
43	Injection into the Longus Colli Muscle via the Thyroid Gland. <b>2019</b> , 9,	3

42 Cervical Dystonia. **2006**, 137-153

41 Botulinum Toxins in the Treatment of Dystonia. **2006**, 355-370

1

40 Nonmotor Symptoms in Dystonia. **2006**, 289-300

39 Treatment of Dystonia. **2007**, 345-367

38 Psychogenic dystonia. **2007**, 183-194

37 13 Tratamiento de la espasticidad con toxina botulbica de tipo A. **2010**, 217-242

36 Diagnosis and Treatment of Primary (Idiopathic) Dystonia. 191-206

35 Bewegungsstörungen. **2011**, 955-1054

34 Movement Disorders. **2012**, 115-159

33 Nonmotor symptoms in dystonia. **2012**, 320-338

32 Botulinum toxins in the treatment of dystonia. **2012**, 413-435

31 RimabotulinumtoxinB. **2012**, 452-462

30 OnabotulinumtoxinA: BOTOX® . **2012**, 436-451

29 Dystonia. **2014**, 43-68

28 Botulinum Toxin Injections for Spasticity. **2014**, 103-107

27 Botulinum Neurotoxins as Therapeutics. **2014**, 553-590

26 Clinical Use of Botulinum Neurotoxins: Pain. **2014**, 153-176

25 Patterned or Repetitive Movements and/or Abnormal Posturing. **2016**, 265-303

24	Botulinum Toxin Treatment in Cerebrovascular Disease. <b>2018</b> , 213-230		1
23	Idiopathische Dystonien. <i>Springer Reference Medizin</i> , <b>2018</b> , 1-17	0	
22	Rehabilitation Following TBI. <b>2020</b> , 293-327		1
21	Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan. <i>ENeurologicalSci</i> , <b>2021</b> , 25, 100374	2.1	0
20	Idiopathische Dystonien. <i>Springer Reference Medizin</i> , <b>2020</b> , 1341-1357	0	1
19	Evidence-Based Review of Current Botulinum Toxin Treatment Indications in Medicine. <b>2020</b> , 43-112		
18	Sialorrhoea and Frey's Syndrome. <b>2007</b> , 123-135		
17	Botulinum toxin type A in the treatment of patients with cervical dystonia. <i>Biologics: Targets and Therapy</i> , <b>2009</b> , 3, 1-7	4.4	18
16	Dystonia. <i>Clinical Evidence</i> , <b>2008</b> , 2008,		2
15	Dystonia. <i>Clinical Evidence</i> , <b>2011</b> , 2011,		4
14	Dystonia. <i>Clinical Evidence</i> , <b>2014</b> , 2014,		2
13	Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A. <i>Drugs</i> , <b>2021</b> , 81, 2091-2101	12.1	0
12	Cell-Penetrating Botulinum Neurotoxin Type A With Improved Cellular Uptake and Therapeutic Index.. <i>Frontiers in Bioengineering and Biotechnology</i> , <b>2022</b> , 10, 828427	5.8	0
11	Treatment of Dystonic Pain with Botulinum Neurotoxins. <b>2022</b> , 235-253		
10	DaxibotulinumtoxinA for injection: A review of the current data. <i>Dermatological Reviews</i> ,	0.2	
9	Botulinum Toxin Injections for Spasticity. <b>2022</b> , 145-152		
8	OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE. <i>Frontiers in Neurology</i> , 13,	4.1	
7	Botulinum Toxin in the Treatment of Cervical Dystonia: Evidence-Based Review. 1,		1

- 6 Long-term efficacy with deep brain stimulation of the globus pallidus internus in cervical dystonia: a retrospective monocentric study. **2022**, 4,
- 5 Botulinumtoksin - en oversikt over mulige bruksområder innen oral og maxillofacial kirurgi. **2012**, 122,
- 4 How adjusting elicited health utilities after the fact can adversely affect shared decision making. 11, 1533
- 3 The Effect of Pyridostigmine as an Antidote for Botulinum Type A: An Experimental Study on Rabbits. 11, 1547
- 2 Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials. **2023**, 15, 60
- 1 Botulinum Neurotoxins as a Therapeutic. **2022**, 1095-1143